Proof of Concept Study to Access Superficial Basal Cell Carcinoma in Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

April 17, 2023

Primary Completion Date

March 7, 2024

Study Completion Date

March 7, 2024

Conditions
Superficial Basal Cell Carcinoma
Interventions
DRUG

Tirbanibulin Ointment 1%

Klisyri® ointment is a microtubule inhibitor for topical use and is currently on the market for the treatment of actinic keratosis of the face or scalp. The chemical name of tirbanibulin is N-benzyl-2-(5-(4-(2- morpholinoethoxy)phenyl)pyridin-2-yl) acetamide. Tirbanibulin ointment 1% contains 10 mg tirbanibulin per gram of white to off-white ointment containing mono- and di-glycerides and propylene glycol and is supplied in packets containing 250 mg of tirbanibulin ointment 1%. Each packet includes single-dose packets (2.5 mg tirbanibulin in 250 mg) to be applied to evenly cover up to 25 cm² of the treatment field once daily for 5 consecutive days using 1 single-dose packet per application.

Trial Locations (1)

78660

Austin Institute for Clinical Research, Inc., Pflugerville

All Listed Sponsors
lead

Austin Institute for Clinical Research

NETWORK